Comparison of RECIST 1.1 and irecist in patients treated with immune checkpoint inhibitors: A systematic review and meta-analysis

Hyo Jung Park, Gun Ha Kim, Kyung Won Kim*, Choong Wook Lee, Shinkyo Yoon, Young Kwang Chae, Sree Harsha Tirumani, Nikhil H. Ramaiya

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

3 Scopus citations


Despite wide recognition of iRECIST, evidence regarding the impact of iRECIST over RECIST 1.1 is lacking. We aimed to evaluate the impact of iRECIST on assessing treatment efficacy of immune checkpoint inhibitors (ICIs) over RECIST 1.1. Articles that evaluated the treatment response and outcome based on both RECIST 1.1 and iRECIST were eligible. Data regarding overall response rates (ORR) and disease control rate (DCR) based on RECIST 1.1 and iRECIST, and data required to estimate individual patient data of progression-free survival (PFS) were extracted. Estimates were compared using meta-regression and pooled incidence rate ratios. The pooled difference of restricted mean survival time (RMST) of PFS between two criteria were calculated. Eleven studies with 6210 patients were analyzed. The application of iRECIST had no impact on the response-related endpoint by showing no significantly different ORR and DCR from RECIST 1.1 (pooled ORR, 23.6% and 24.7% [p = 0.72]; pooled DCR, 45.3% and 48.7% [p = 0.56] for iRECIST and RECIST 1.1, respectively) and had a minor impact on a survival endpoint by showing longer RMST of PFS than RECIST 1.1 (pooled difference, 0.46 months; 95% CI, 0.10–0.82 months; p = 0.01). Such a modest benefit of iRECIST should be considered when we design a clinical trial for immune checkpoint inhibitors.

Original languageEnglish (US)
Article number120
Pages (from-to)1-14
Number of pages14
Issue number1
StatePublished - Jan 1 2021


  • Checkpoint inhibitor
  • Immunotherapy
  • Treatment efficacy

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'Comparison of RECIST 1.1 and irecist in patients treated with immune checkpoint inhibitors: A systematic review and meta-analysis'. Together they form a unique fingerprint.

Cite this